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Abstract
Cellular immune responses during acute Hepatitis C virus (HCV) and HIV infection are a known correlate of infection
outcome. Viral adaptation to these responses via mutation(s) within CD8+ T-cell epitopes allows these viruses to subvert
host immune control. This study examined HCV evolution in 21 HCV genotype 1-infected subjects to characterise the level
of viral adaptation during acute and early HCV infection. Of the total mutations observed 25% were within described CD8+
T-cell epitopes or at viral adaptation sites. Most mutations were maintained into the chronic phase of HCV infection (75%).
The lack of reversion of adaptations and high proportion of silent substitutions suggests that HCV has structural and
functional limitations that constrain evolution. These results were compared to the pattern of viral evolution observed in 98
subjects during a similar phase in HIV infection from a previous study. In contrast to HCV, evolution during acute HIV
infection is marked by high levels of amino acid change relative to silent substitutions, including a higher proportion of
adaptations, likely reflecting strong and continued CD8+ T-cell pressure combined with greater plasticity of the virus.
Understanding viral escape dynamics for these two viruses is important for effective T cell vaccine design.
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Introduction
The initial cellular immune response to the Hepatitis C virus
(HCV) plays an important role in viral control following infection
[1,2,3,4,5,6]. Studies in both humans and surrogate animal models
indicate that a strong and durable CD8
+ T-cell response aids in
controlling infection [7,8], however HCV mutations within
immune targets (epitopes) lead to viral escape (adaptations) from
the host’s immune response [9,10,11,12,13]. Information on the
dynamics of viral adaptation during the critical acute phase of
HCV infection is still limited due to the lack of large acute HCV
infection clinical cohorts and the small number of known HCV T
cell epitopes.
Previous studies examining viral evolution during acute and
early HCV infection on a small number of subjects showed that
the proportion of mutations likely to be associated with CD8
+ T-
cell immune pressure varies from 11–25% [9,13]. These results
contrast with those from HIV-1 and SIV studies which suggest
that the proportion of mutations associated with CD8
+ T-cell
immune pressure during acute infection can be greater than 50%
and is a major driving force in HIV evolution [14–16].
Furthermore, a substantial number of early mutations in HIV
are reversions of viral adaptations to non-adapted or wildtype virus
in the absence of the selecting immune pressure [14] suggesting a
fast rate of forward and reverse mutations relative to HCV. The
pattern of viral adaptation in HIV and HCV are often treated as
comparable in discussions of successful anti-viral host immune
responses and vaccine design. However, a direct comparison
between the patterns of viral evolution in these two viruses in the
critical acute phase of infection has not been performed. This
comparison is hampered by the discrepancy between the numbers
of known T-cell epitopes for the two viruses. There is a much
larger number of known T-cell epitopes ([17], Los Alamos http://
hcv.lanl.gov [18] and IEDB [19] http://www.immuneepitope.org)
that cover the HIV proteome at a greater density than within the
HCV proteome. Accordingly, a direct comparison of the
evolutionary dynamics of the two viruses must attempt to account
for these differences.
The selection of viral epitopes presented to CD8
+ T-cells is
restricted by the repertoire of human leucocyte antigen (HLA)
class I molecules present in the infected host. To date, the number
of known T-cell epitopes for HCV is relatively limited and there is
an over-representation of epitopes restricted to common HLA
types (e.g. HLA-A2). More recently, as an alternative approach to
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tion-based genetic studies have found statistically significant
associations between polymorphisms within the viral genome
and specific HLA types [20,21,22]. These putative viral adaptation
sites are likely to mark in-vivo T-cell targets and indeed several of
these sites have been shown to fall within known T-cell epitopes
with the appropriate HLA-restriction and escape pattern
[20,21,22]. These viral adaptation sites may represent additional
sites of HCV-specific T-cell targets for a broader range of HLA
types present in human populations that can complement the
existing databases of published HCV-specific T-cell epitopes and
provide a better framework to study HCV adaptation to HLA-
restricted immune responses during infection.
In this study we examine the dynamics of viral evolution and
specifically viral adaptation during acute and chronic HCV
infection in sequential sequences from 21 HCV-genotype 1
infected individuals with different outcomes. We circumvent, to
some extent, the issue of limited published HCV epitopes by
including in the analysis putative viral adaptation sites from
genetic-based studies [20,22]. We then compare viral evolution
during the critical acute to chronic infection phase between HIV
and HCV utilising HIV sequences obtained from a published
longitudinal study on acute HIV infection (n=98; [14]) which also
utilised viral adaptation sites from genetic-based studies. Though
the HIV studies have had much larger cohort sizes, this approach
allows a more comparable evaluation of the evolution of these two
viruses during this critical phase of infection. The comparison
between the viruses reveals differences in their mode of evolution,
including in response to T-cell immune pressure.
Results
Mutations during acute and early HCV infection
In this analysis, mutations are defined as non-synonymous
nucleotide changes that occur during infection relative to the first
sampled time-point (T0). For many subjects this first time-point is
within 3–4 months after estimated HCV exposure (median 10
weeks, mean 11.5 weeks) and often coincides with clinical acute
hepatitis and jaundice. Subsequent follow-up sampling occurred at
a median of 56 weeks (mean 61.2 weeks). All 21 study subjects
were infected with genotype 1 and clinical parameters and
sampling information for each subject is listed in Table 1. To
increase subject numbers, four subjects from the Kuntzen et al
study [13] were included in this analysis.
Analysis of the HCV non-structural protein NS2-NS5B sequenc-
es from sequential time-points of subjects with acute and early HCV
infection revealed a total of 170 amino acid changes, the majority of
which were maintained into chronic infection (108/143 mutations
in subjects with multiple time-points; Table S1). We then examined
each of the proteins separately and found, consistent with other
studies [22,23], that NS2 exhibited the greatest variability within a
subject, with NS3 being the most conserved protein (mean genetic
distance for genotype 1a subjects NS2=0.019–0.06, NS3=
0.005–0.018, NS4=0.006–0.026, NS5A=0.02–0.045, NS5B=
0.01–0.019).
To determine if there was a higher rate of change during the
acute phase compared to later time-points, as previously suggested
[13], we separated the sampling time-points into three intervals 0–
24 weeks, 24–48 weeks and 48–72 weeks from time of infection.
For each individual we considered the cumulative genetic
distances for both changes incurring amino acid change
(nonsynonymous mutation) and silent (synonymous) mutations at
each time-point (Table S2). Based on this analysis we found no
evidence of differential rates of change in the three time intervals
for either nonsynonymous (p=0.18) or synonymous changes
(p=0.43). We did not have multiple time-points from individuals
that naturally resolved infection and hence we are observing viral
evolution in the context of a failed immune response with or
without interferon alpha treatment.
Mutations occur at sites likely to be under host HLA
allele-specific immune pressure (viral adaptation)
To investigate the level of change in regions targeted by HLA-
specific T-cell pressure, we counted the number of mutations
within described T-cell epitopes (Los Alamos http://hcv.lanl.gov
[18] and IEDB http://www.immuneepitope.org [19]) and puta-
tive T-cell targets marked by adaptation sites from genetic-based
studies [20,22].
Of the total number of mutations observed, 25.3% (43/170)
occur at sites likely to be under HLA-specific CD8
+ T-cell immune
pressure (Table S1). Overall, the HCV proteins differ in the
percentage of mutations presumed to be under T-cell immune
pressure (12% for NS2, 46.4% for NS3, 21.4% for NS4, 24.4% for
NS5A and 22.4% for NS5B) but this probably reflects the number
of known and predicted T-cell targets in each protein examined in
this study (17 for NS2, 47 for NS3, 25 for NS4, 19 for NS5A and
25 for NS5B). Most of these mutations are maintained into the
later phase of infection. In addition, we observe mutations as late
Table 1. Subject characteristics.
Subject ID Sampling timepoints GT HLA-A HLA-B Outcome
(weeks)
#
SR1 11 1a 1/1 8/44 SR
SR2 11 1b 2/25 15/44
SR3 12 1b 3/24 15/35
TR1 7, 20 1a 1/24 8/57 TR
TR2 13, 21, 25 1a 2/26 38/50
TR3 8, 26, 32 1b 2/3 7/7
TR4 19, 21, 44, 60 1b 2/24 18/44
TR5 8, 14 1b 2/28 27/51
TR6 9, 27 1b 3/25 7/18
TR7 7, 8 1b 3/24 7/1501
C1 14, 23, 38, 45, 92, 127,
193, 232
1a 2/24 18/44 C
C2* 15, 19 1a 26/26 49/55
C3 12, 58, 78, 143 1a 11/31 40/51
C4 9, 14, 76 1a 2/3 7/44
C5 8, 12, 37, 56 1b 29/68 7/14
C6 21, 82, 109, 121 1b 2/24 18/60
C7 32, 63 1b 2/23 41/44
BR554 8, 28, 60, 76 1a 2/31 39/51
BR111* 10, 30, 58, 94, 118 1a 2/23 44/44
03–32 8, 36, 106 1a 1/3 8/35
BR1427* 0, 4, 22, 56 1b 26/29 15/15
#Time since infection was estimated from the known time since onset of
symptoms corresponding to approx. 7 weeks or seroconversion
corresponding to 6 weeks.
*Acquisition of HCV via needle-stick injury or surgery. SR-Spontaneous Resolver,
TR-Therapy Resolver, C-Chronic, GT-genotype. BR554, BR111, 03-32 and BR1427
are from [13].
doi:10.1371/journal.pone.0016797.t001
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of therapy (eg C1 NS5B) within published HLA-A and -B-
restricted epitopes (Table S1), indicating ongoing immune
pressure or compensatory mutations late in infection and during
or after interferon treatment.
The proportion of mutations falling within known and predicted
T-cell targets varies substantially between subjects from 0% to
100% (Table S1). Although the examination of viral adaptation
sites as listed by recent genetic studies [20,21,22] allows for the
identification of putative sites under immune pressure for HLA
types not commonly represented in the literature as well as those
epitopes that are more variable and hence may not be detected
with more traditional cellular approaches, the number of known
and predicted viral immune targets for each subject still differs
depending on their HLA repertoire (Table S1). Subjects with less
common HLA types will inevitably have less T-cell targets in our
pre-defined list and tend to correspond to values at the lower end
of this range.
Existing HCV adaptation to the host’s HLA-restricted
immune response at the first sampling time-point
The number of viral adaptations already present within the
virus at the first sampling time-point is shown in Figure 1 and
Table S3. For many subjects, the first sampling time-point was
within 2–4 months of infection and existing viral adaptations could
have resulted from mutations very early in the acute phase of
infection. However, subject BR1427 already has an existing
mutation within an HLA-matched epitope in NS2 close to the
time of infection, which is unlikely to be due to T-cell pressure at
this stage and may represent the transmission of a viral adaptation
induced in the previous host. For viral adaptations within known
T-cell epitopes and putative viral adaptation sites evident at the
first sampling time-point, these amino acids are predominantly
maintained throughout infection.
There is no obvious difference in the amount of viral adaptation
at the first time-point between subjects that go on to become
chronically infected and those who spontaneously clear the virus,
although limited numbers here for each outcome restrict a more
formal comparison.
Amino acid reversion of viral adaptations in non-HLA
matched subjects occurs rarely during the course of
infection
We examined reversion to consensus (non-adapted) sequence of
incoming variations within epitopes and at putative viral
adaptation sites that were restricted by HLA alleles not present
in the subject (Figure 1 and Table S3). In NS3 alone, a total of 35
variations within known T-cell epitopes or at putative viral
adaptation sites restricted by HLA types that are not present in the
newly infected hosts existed at the first time-point of which only 3
reverted to non-adapted sequence. Overall there was limited
reversion observed in all subjects (11/207 revert to wildtype;
Figure 1 and Table S3). If these reversions are added to the
number of mutations associated with T-cell immune pressure it
slightly increases the proportion from 25.3% to 31.8%.
The lack of reversion within HLA-restricted HCV T-cell
epitopes and viral adaptation sites may suggest that mutations at
these sites have limited impact on viral fitness or the cost is offset
by compensatory mutations that prevent simple reversion. For
some of these changes it may be that they do not revert over-time
because they may not necessarily affect peptide presentation or T-
cell receptor binding and do not incur a fitness cost as previously
discussed.
Preservation and accumulation of mutations in potential
protective epitopes
The apparent lack of reversion described above for HCV may
lead to the transmission of sequences harbouring mutations within
epitopes that facilitate escape from protective CD8
+ T-cell
responses. In HIV infection the accumulation of mutations within
epitopes has been previously described and it has been postulated
that it may be required for ultimate viral escape [24,25]. shows
the HLA-B27 NS5B epitope which has previously been associated
with protection [26] against HCV genotype 1. There are three
Figure 1. Existing sequence variations within CD8
+ T-cell epitopes. Number of existing variations at first sampling time-point within CD8
+ T-
cell epitopes for matching HLA types and non-matching HLA types (relative to ‘‘wildtype’’=HCV reference) and reversions in absence of specific HLA-
restricted immune pressure.
doi:10.1371/journal.pone.0016797.g001
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genetic approach [22] suggesting the need for multiple changes
within the epitope to allow escape. Mutations at these sites within
this T-cell epitope (compared to the known wildtype sequence)
occur even in subjects that are not HLA-B27 positive and are
maintained, facilitating an enrichment of variation. However, it is
only in subject TR5 who expresses HLA-B27 that all three viral
adaptation sites exist as the escaped form. A recent study by
Dazert and colleagues has shown that the accumulation of
mutations within the HLA-B27 NS5B epitope is required for
escape from T cell recognition [27]. Furthermore, analysis of their
own published data showed that variation versus consensus at
three sites within this epitope is not observed in acute infected
subjects who are HLA-B27 negative as also shown in our study.
Pattern of viral evolution during acute to early chronic
infection in HCV differs to that observed for a similar
phase in HIV infection
The appearance of viral adaptations to a host’s immune
response likely reflects the onset of the immune response in the
individual, the intrinsic mutation rate of the virus, the balance
between benefit and fitness cost of mutation(s) and codon usage
within selected infecting virus(es). Functional constraint (amount of
intolerance towards nucleotide substitution) within the viral
genome can be estimated by the rate of nonsynonymous and
synonymous substitutions. In this approach, synonymous substi-
tutions are thought to be neutral and representative of the
mutation rate while the nonsynonymous rate reflects the balance
between the mutation rate and purifying selection of deleterious
mutations. [28]. We compared these changes in HCV and HIV, as
the ability of the viruses to mutate to adapt to host immune
pressure or revert to wildtype in the absence of specific immune
pressure appears to differ and may reflect different constraints on
these viruses. The HCV sequences described above were
compared to the HIV sequences obtained from the recent study
by Brumme and colleagues [14] during a similar phase of infection
(median 425 days follow-up) and the results revealed different
patterns of mutation as reflected in the number and rate of
nonsynonymous and synonymous change (Figure 3 and Table 2).
For HCV, rate and number of synonymous changes are greater
than that observed for nonsynonymous changes. In contrast, HIV
has a greater number (and in some cases the rate) of nonsynon-
ymous changes than synonymous changes. The differences in the
pattern of evolution for the two viruses is consistent with what is
observed when you compare viral sequences from cross-sectional
studies of chronic HIV [29] and HCV [22] subjects from the same
geographical area and using similar sequencing methods (Table 2).
The number of putative viral adaptations found in this study is
consistent with others [9,13] but is less than that observed for HIV
during a similar phase of infection (30–60% for Gag, Pol and Nef)
[14]. In the present study we defined adaptation as change within
a published T-cell epitope (n=96) or at a putative viral adaptation
site (n=36) in the NS2-NS5B region of which 9 sites were within
known HCV T-cell epitopes. In the recent Brumme et al study on
HIV [14] the authors defined adaptation as change occurring at
an adaptation site within a known T-cell epitope (n=71). The
adaptation sites in the HIV study were identified using the same
approach as described for HCV. Although the present study
attempts to allow a comparable analysis of the evolution of the two
viruses by using the same analytical approaches, some of the
mutations within known HCV T-cell epitopes may not necessarily
be associated with specific host immune pressure (as discussed
earlier). However, irrespective of this limitation, it does appear that
the proportion of mutations associated with T-cell pressure is
higher in HIV (30–60%) than for HCV (31.8%).
Discussion
Acute HCV infection is difficult to study due to the lack of
clinical disease around the time of viral inoculation. This study
aims to assess viral evolution during the first months of infection
and at a time when clinical disease of hepatitis and/or jaundice is
Figure 2. HCV sequences in different subjects for the HLA-B*27
epitope in NS5B. Single asterick indicates site of HLA-association
based on 2-digit HLA typing and double asterick based on 4-digit HLA
typing. Dots indicate identity to consensus. Numbering indicates
position with the NS5B protein. Black indicates subject with HLA-
B*27. Dark grey box indicates time-points after cessation of therapy.
doi:10.1371/journal.pone.0016797.g002
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acute phase of infection, maintenance of these changes into
chronic infection and little evidence of early reversion.
Overall, HCV evolution occurs to a limited extent and
accumulates overtime. Part of these results may have been
expected as HCV infection is associated with a narrow and often
functionally impaired T cell response that can be maintained,
albeit at a low level and detectable mainly in hepatic lymphocytes
during persistent infection [30,31,32]. The maintenance of viral
adaptations may therefore reflect ongoing T-cell pressure in
chronic HCV-infected subjects. Alternatively, preservation of
changes could be the result of linked compensatory mutations
that stabilize the primary escape mutation and/or improve viral
function. On the other hand, these mutations may be well
tolerated by the virus and have no or little impact on viral fitness
and function. Functional studies assessing viral replication may
clarify further the importance of these mutations.
Surprisingly we were unable to show a clear difference between
the rate of viral evolution during acute and the chronic phase of
infection, as generally the early phase of infection is associated with
a stronger T-cell response that can coincide with clinical hepatitis
and jaundice [5,30]. However, adaptations were already present in
several subjects at the first sampling timepoint and some of these
may have occurred before the first sampling timepoint.
We also found examples where mutations within known T-cell
epitopes occur at later time-points during early chronic phase and
particularly in one case after cessation of treatment. These late
changes may reflect new emerging T-cell pressure targeting novel
viral regions at later stages of infection or the ongoing ‘‘editing’’ of
the HCV genome with secondary mutations stabilizing primary
escape mutations, potentially increasing viral fitness. Interestingly,
previous studies on HCV have found little or no evidence of new
T-cell responses after the first six months of infection [13,30].
Furthermore, the appearance of changes after treatment cessation
Figure 3. Plot of synonymous and non-synonymous changes during acute and early infection for HCV (A and B) and HIV (C and D).
Representative subjects are shown that had similar sampling time-points. Time-points for HIV subjects were determined by adding 4 weeks to first
time-points to represent time since infection.
doi:10.1371/journal.pone.0016797.g003
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distribution of viral populations via the reduction of viral
heterogeneity through bottlenecks and/or increased T-cell pres-
sure on the virus during therapy. Further studies are needed to
clarify the effect of therapy on viral adaptation.
The lack of reversion over-time of pre-existing viral adaptations
in subjects without the relevant HLA type suggest that these
changes may require compensatory mutations that do not allow
simple reversion, therefore allowing the accumulation of mutations
and transmission of pre-adapted viruses. In contrast, a large
number of the mutations associated with CD8
+ T-cell pressure
observed during the acute phase of HIV infection in the Brumme
et al study were reversions in the absence of HLA-restricted
immune pressure (,70%); many of which are escape mutations
known to incur a fitness cost [14].
In this study, we were unable to directly assess if the changes
observed in subjects were within regions under CD8
+ T-cell
pressure using cellular assays due to the lack of available peripheral
blood cells. Accordingly, changes in described epitopes and
adaptation sites included in this analysis are assumed to represent
viral escape mutations in the study subjects. We acknowledge that
some of these changes may not be true escape mutations, however,
many of the predicted adaptations from the genetic study fall at
known escape sites [20,22] and Figure S1 shows a diminished IFN-
gamma response to a variant peptide with a novel variation
(observed in subjects C1 and C4) in a described epitope compared
to the consensus peptide in samples from a chronically HCV
infected subject (not part of the acute study cohort). Furthermore,
previous studies examining mutations associated with detectable
CD8
+ T-cell responses during acute HCV infection showed that a
number of variant peptides (most unconfirmed escape mutations)
of described epitopes resulted in either loss or reduction of T-cell
recognition [9]. Taken together, these results suggest that many of
the variants observed within known epitopes and at adaptation
sites in this study are likely to impact on T cell recognition.
Despite limitations in the study, the 25.3% adaptation rate
obtained in this study is comparable to the rate obtained by Kuntzen
et al (11% overall and 20.8% during the acute phase for non-
envelope mutations; [13]) on four subjects during acute HCV
infection that were also analysed in this study. Kuntzen and
colleagues were able to directly correlate CD8
+ T-cell responses to
peptides covering the HCV genome with sequence evolution in the
autologous virus and, for the most part, reduced T-cell recognition
for the variant peptide. In addition, an earlier study by Cox and
colleagues on HCV evolution during the first six months after acute
infection showed a comparable rate of 25% of mutations were in
detected CD8
+ T-cell responses [9], although this number was about
50% when only mutations outside the envelope were included.
Finally, when the rate and number of amino acid changes relative
to silent mutations is compared between HIV and HCV in a similar
phase of infection, HCV appears to have a greater proportion of
silent mutations than HIV. In addition, the observation of a higher
proportion of mutations associated with CD8
+ T-cell pressure,
including reversions, in HIV compared to HCV highlights key
differences in the strength of selection pressures on these two viruses,
that is their plasticity and ultimately their ability to escape CD8
+ T-
cellresponses.Understanding viral escape dynamics in early infection
in these two infections is of primary importance for effective T cell
vaccine design and may also imply different drug resistance dynamics
in HIV and HCV when exposed to anti-viral drugs.
Materials and Methods
Subjects
Plasma samples from 17 individuals with acute HCV genotype 1
infection (7, 1a; 10, 1b) were collected at the Klinikum Grosshadern
in Munich, Germany between 1994 and 2005. Acute or early phase
of HCV infection was defined as 4 months from the onset of
symptoms, commonly jaundice or as 6 months after a known
infection event. After acute infection, three individuals spontane-
ously resolved their HCV infection (SR), 7 cleared after IFN-a
based therapy (TR) and 7 progressed to chronic infection. Table 1
shows details of the study participants. Two-digit HLA-A and -B
typing and clinical data such as viral load (VL) and therapy details
were available for each individual. In addition, sequences from four
HCV genotype 1-infected individuals previously described by
Kuntzen et al [13] were obtained from Genbank and were analysed
with the samples obtained from the Munich subjects.
Ethics Statement
All patients gave written informed consent to participate in the
study and the protocol and the procedures of the study were
Table 2. Mean within and between individual synonymous and nonsynonymous rate for HIV and HCV
*.
Virus Protein acute (n) dN dS dS-dN chronic (n) dN dS dS-dN
HCV
NS2 8 0.0019 0.0038 0.0021 49 0.041 0.194 0.153
NS3 9 0.0011 0.0051 0.004 50 0.011 0.2 0.189
NS4 9 0.0015 0.01 0.0085 39 0.014 0.213 0.198
NS5A 14 0.0018 0.0092 0.0074 48 0.03 0.178 0.149
NS5B 11 0.0016 0.0072 0.0056 41 0.014 0.135 0.121
HIV
‘
GAG 96 0.0018 0.0019 0.0001 138 0.041 0.126 0.085
POL 97 0.001 0.0019 0.0009 130 0.031 0.112 0.08
NEF 92 0.0062 0.0042 20.002 105 0.103 0.151 0.048
*dN and dS computed using the Modified Nei and Gojobori method (MEGA v4). Intra-individual values for acute infection cohorts and inter-individual values for chronic
infection cohorts. Two time-points used for analysis - 1st time-point (T0) within 3–4 months of infection and 2nd time-point closest time-point to 1 year from T0.
n=number of subjects.
‘HIV sequences from [14]. dS-dN summed for all subjects and then divided by number of total subjects (for acute subjects). HCV genotype 1a sequences from cross-
sectional chronic cohort in [22]. HIV clade B sequences from cross-sectional chronic cohort in [29].
doi:10.1371/journal.pone.0016797.t002
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Declaration of Helsinki and according to study protocols approved
by the institutional review board (University Hospital Munich).
Bulk HCV sequencing
Viral RNA was extracted from plasma samples using the
COBAS AMPLICOR HCV Specimen Preparation Kit v2.0
(Roche) according to manufacturer’s instructions. Bulk sequencing
of HCV NS2-NS5 was performed as previously published [22].
Sequence coverage for each protein in each subject is shown in
Table S4 (GenBank accession numbers HM746802-HM746915).
Figure S2 shows the HCV NS3 and NS5B phylogenetic trees with
the well-supported individual subject clusters and separation into
genotype 1A and 1B groups. The trees also show the limited intra-
subject diversity compared to the diversity observed between the
subjects.
HCV sequence analysis
Analysis of sequence evolution during acute and early
HCV infection. For each individual we considered the
cumulative genetic distances at each time point observed. The
times were then broken into 0–24 weeks, 24–48 weeks and 48–72
weeks. Only a small number of cases had data beyond this so we
only considered mutational change over 0–72 weeks and analysed
the relative rates of increase in the three time periods. Estimates in
the 0–24 week range were based on the period from first measure
to 24 weeks and were scaled accordingly. It was assumed that the
cumulative changes could be approximated by a continuous
piecewise linear function with possible rate changes at 24 and 48
weeks. The analysis was carried out using linear mixed models
incorporating correlations between sequence changes within the
same protein and proteins within the same individual. Analyses
were carried out in S+ and rates compared using likelihood ratio
tests.
Genetic diversity. Intra- and inter-subject genetic distances
were calculated using the modified Nei-Gojobori method for both
synonymous and nonsynonymous sites using MEGA v4 software.
Highlighter plots. Aligned longitudinal sequences for both
HCV and HIV-infected subjects were examined for synonymous
and nonsynonymous changes using the highlighter program
available at http:www/hiv.lanl.gov.
Phylogenetic analysis. Phylogenetic trees were constructed
using the neighbor-joining method based on the Kimura-2-
parameter model with 500 bootstrap replications. All analyses
were performed using MEGA v4 software.
Assessment of HCV adaptation
HCV sequences were aligned against the consensus sequences
for genotype 1a and 1b obtained from previous genetic studies
[20,22]. Initially, the HCV genotype sequences were scanned for
sequence changes within known HLA-A and -B-restricted epitopes
within NS2-NS5 (Los Alamos and IEDB databases). Next,
sequence changes were compared to four and two-digit HLA-A
and -B-associated viral polymorphisms observed within HCV
chronic infection cohorts [21,22]. De-novo mutations were defined
as newly occurring changes (as compared to the first sequence
time-point) within known epitopes or at HLA-association sites
relevant for the host’s HLA. Reversion events were defined as
changes back to the sequence at the initial time-point, which
included at sites within or outside known epitopes or at HLA-
association sites relevant for the host’s HLA.
Supporting Information
Figure S1 Reduced IFN-gamma production for variant
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